Processa Pharmaceuticals (NASDAQ: PCSA) — Perfil da empresa, notícias e dados financeiros
Processa Pharmaceuticals develops drugs aimed at improving survival and quality of life for patients with high unmet medical needs.

Processa Pharmaceuticals
Processa Pharmaceuticals (NASDAQ:PCSA) is focused on developing drugs that are intended to improve the survival and/or quality of life for patients who have a high unmet medical need. With a keen eye on advancing their portfolio, their projects currently span across various stages of clinical and preclinical development. They aim to leverage their scientific expertise to bring novel therapies to market, specifically targeting conditions that lack effective treatments. Their objectives center on rigorously pushing their research and development pipeline while ensuring safety and efficacy in their therapeutic solutions, ultimately striving to address the significant gaps in patient care.
Resumo
Operações
Produtos e/ou serviços de Processa Pharmaceuticals
- Development of PCS499, an oral tablet designed to treat Necrobiosis Lipoidica, a chronic, disfiguring condition.
- Investigating PCS12852, aimed at addressing gastrointestinal disorders, focusing on functional constipation.
- Advancing PCS6422, a cancer treatment adjunct focusing on enhancing the efficacy of standard chemotherapy drugs.
- Work on PCS11T, targeting advanced solid tumors, offering a new approach to cancer therapy.
- Research into PCS3117, a potential treatment for pancreatic cancer, aiming to improve patient outcomes.
- Exploration of PCS100, a novel therapy for pulmonary arterial hypertension, seeking to address severe heart and lung complications.
equipe executiva do Processa Pharmaceuticals
- George K. NgCEO & Director
- Russell L. SkibstedChief Financial Officer
- David YoungCo-Founder, President of Research and Development & Director
- Patrick LinCo-Founder, Chief Business & Strategy Officer
- Wendy J. GuyCo-Founder, Chief Administrative Officer & Corporate Secretary
- Steven ChaSenior Vice President of Clinical Research
Últimas notícias sobre a Processa Pharmaceuticals
Comunicados recentes
O que a Processa Pharmaceuticals (PCSA) comunicou ao mercado, do mais recente para o mais antigo.
- 10-Q | Processa Pharmaceuticals, Inc.
- LULD halt | PCSAFato relevante
Principais indicadores financeiros
Resultados divulgados pela Processa Pharmaceuticals, em USD.
- Cap. de mercado
- 4,8 mi
- Receita (TTM)
- 0
- P/L
- —
- LPA (diluído, TTM)
- -4.3
- Dividend yield
- —
- Margem de lucro
- 0.0%
| Fim do ano fiscal | Receita | Resultado operacional | Lucro líquido |
|---|---|---|---|
| 0 | -14 mi | -13,6 mi | |
| 0 | -12,1 mi | -11,9 mi | |
| 0 | -11,5 mi | -11,1 mi | |
| 0 | -20,3 mi | -27,4 mi |